1921
Volume 39, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645
USD

Abstract

Abstract

Trimetrexate is a lipid-soluble antifolate that has been shown in vitro to be a much more potent inhibitor of dihydrofolate reductase than the conventionally used inhibitor trimethoprim. To evaluate the in vivo efficacy of trimetrexate, steroid-treated rats which spontaneously develop pneumonia were used. Rats treated with trimetrexate (25 mg/kg/d) plus sulfamethoxazole (250 mg/kg/d) orally responded at least as well as rats treated with trimethoprim (50 mg/kg/d) plus sulfamethoxazole. Trimetrexate alone administered orally was ineffective in treating infection, but subcutaneous (sc) trimetrexate (7 mg/kg/d) significantly decreased the intensity of infection compared to controls. Trimetrexate is a potent antifolate that may provide an effective alternative to pentamidine and trimethoprim-sulfamethoxazole for treatment of pneumonia in humans.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.1988.39.491
1988-11-01
2017-09-20
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.1988.39.491
Loading
  • Accepted : 17 Apr 1988

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error